接受新辅助放化疗（NCRT）联合手术治疗的食管鳞状细胞癌（ESCC）患者的生存预测参数尚不清楚。在这里，我们的目的是根据治疗前血清学肝肾功能测试构建列线图，用于 NCRT 联合手术治疗的 ESCC 患者的生存预测。 2007年7月至2019年6月，共有174例诊断为ESCC的患者被纳入训练队列，其中约50%的病例（n = 88）被随机选择作为内部验证队列。进行单变量和多变量 Cox 生存分析以确定独立的预后因素以建立列线图。通过 Harrell 一致性指数（C 指数）和校准曲线评估列线图的预测准确性。 ALT、ALP、TBA、TP、AST、TBIL 和 CREA 被确定为独立的预后因素，并纳入肝肾功能测试列线图 (HRFTNomogram) 的构建中。训练组中总生存期（OS）HRFT诺模图的C指数为0.764（95% CI 0.701-0.827），高于TNM分期系统的C指数（0.507（95% CI 0.429-0.585），P < 0.001)。训练队列的 5 年 OS 校准曲线表明 HRFTNomogram 的预测准确性令人满意。此外，训练队列中按 HRFTNomogram 分层的高风险组患者的 5 年 OS 低于低风险组患者（27.4% vs. 80.3%，P<0.001）。在内部验证队列中也观察到了类似的结果。一种新颖的 HRFT 列线图可能有助于预测接受 NCRT 治疗后行食管切除术的局部晚期 ESCC 患者的生存率。© 2023。意大利外科学会 (SIC)。

The parameters for survival prediction of esophageal squamous cell carcinoma (ESCC) patients treated with neoadjuvant chemoradiotherapy (NCRT) combined with surgery are unclear. Here, we aimed to construct a nomogram for survival prediction of ESCC patients treated with NCRT combined with surgery based on pretreatment serological hepatic and renal function tests. A total of 174 patients diagnosed as ESCC were enrolled as a training cohort from July 2007 to June 2019, and approximately 50% of the cases (n = 88) were randomly selected as an internal validation cohort. Univariate and multivariate Cox survival analyses were performed to identify independent prognostic factors to establish a nomogram. Predictive accuracy of the nomogram was evaluated by Harrell's concordance index (C-index) and calibration curve. ALT, ALP, TBA, TP, AST, TBIL and CREA were identified as independent prognostic factors and incorporated into the construction of the hepatic and renal function test nomogram (HRFTNomogram). The C-index of the HRFTNomogram for overall survival (OS) was 0.764 (95% CI 0.701-0.827) in the training cohort, which was higher than that of the TNM staging system (0.507 (95% CI 0.429-0.585), P < 0.001). The 5-year OS calibration curve of the training cohort demonstrated that the predictive accuracy of the HRFTNomogram was satisfactory. Moreover, patients in the high-risk group stratified by the HRFTNomogram had poorer 5-year OS than those in the low-risk group in the training cohort (27.4% vs. 80.3%, P < 0.001). Similar results were observed in the internal validation cohort. A novel HRFTNomogram might help predict the survival of locally advanced ESCC patients treated with NCRT followed by esophagectomy.© 2023. Italian Society of Surgery (SIC).